Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23

NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy

Read More

Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23

NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343

Read More

Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Read More

Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Read More

Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

Read More

Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22

FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis

Read More

Press release Stine Krag Brunvold 5/10/22 Press release Stine Krag Brunvold 5/10/22

NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer

Read More

Press release Stine Krag Brunvold 5/3/22 Press release Stine Krag Brunvold 5/3/22

NMD Pharma expands its US presence

Read More

Press release Stine Krag Brunvold 2/15/22 Press release Stine Krag Brunvold 2/15/22

NMD Pharma Raises €35 Million in a new Financing

Read More

Press release Stine Krag Brunvold 7/8/21 Press release Stine Krag Brunvold 7/8/21

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease

Read More

Press release Stine Krag Brunvold 6/30/21 Press release Stine Krag Brunvold 6/30/21

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

Read More

Press release Stine Krag Brunvold 6/1/21 Press release Stine Krag Brunvold 6/1/21

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Read More

Press release Stine Krag Brunvold 11/30/20 Press release Stine Krag Brunvold 11/30/20

NMD Pharma Moves Corporate Headquarters to INCUBA to Support Future Growth

It all begins with an idea.

Read More

Press release Stine Krag Brunvold 11/30/20 Press release Stine Krag Brunvold 11/30/20

NMD Pharma Receives Grant from The Innovation Fund Denmark

It all begins with an idea.

Read More

Press release Stine Krag Brunvold 10/6/20 Press release Stine Krag Brunvold 10/6/20

NMD Pharma Initiates Combined Phase I/II Clinical trial

It all begins with an idea.

Read More

Press release Stine Krag Brunvold 7/15/20 Press release Stine Krag Brunvold 7/15/20

NMD Pharma begins first clinical trial

It all begins with an idea.

Read More

Press release Stine Krag Brunvold 3/23/18 Press release Stine Krag Brunvold 3/23/18

NMD Pharma raises €38M (USD 47 Million) SERIES A Financing

It all begins with an idea.

Read More